Latest News & Features
Americas
The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies. 20 May 2026
Americas
The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry. 20 May 2026
Americas
In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties". 19 May 2026
Americas
The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza. 19 May 2026
Americas
Success in complex pharmaceutical litigation often comes down to early preparation and cross-functional alignment. This session explores how companies can proactively manage Hatch-Waxman and BPCIA disputes through strategic front-end planning and operational execution. 19 May 2026
Europe
A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions. 18 May 2026
Americas
A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival. 18 May 2026
Europe
Are the EPO and the UPC diverging in their assessment of inventive step? By analysing key recent pharmaceutical decisions, this presentation highlights potential differences in standards and considers how they impact European patent strategies. 18 May 2026
Americas
The intersection of regulatory strategy and intellectual property protection has become critical to maintaining market exclusivity. This panel examines how life sciences companies can adapt their IP strategies in response to shifting FDA guidance, biosimilar challenges, and evolving agency priorities. 17 May 2026
Americas
As antibodies cement their status as a major therapeutic class, securing robust IP protection has grown increasingly difficult. With heightened scrutiny on enablement and written description requirements, this panel unpacks strategies for building resilient antibody portfolios in a challenging global landscape. 16 May 2026